Common Stock
- Symbol
- WINT
- Exchange
- Not supplied
- Classification
- COMMON
Current Report · Items 1.01, 9.01 · 8-K
Windtree Therapeutics, Inc.
WINTOTCEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement As disclosed in a press release dated December 23, 2025, on December 16th, 2025 Windtree Therapeutics, Inc. (“Windtree” or “the Company”) signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. (“SPO”), a Delaware limited liability company.…
Company context
We are a diversified company with several divisions and focused on seeking partnerships and becoming a revenue-generating company through various initiatives. Our operations include pharmaceutical manufacturing as a sourcing agent for Evofem Biosciences, Inc. (“Evofem”), and biotechnology.
Current securities
Historical securities (7)
WINTNASDAQ · EQUITY · Historical · closed Aug 20, 2025WINTOTC · EQUITY · Historical · closed Dec 22, 2017WINTOTC · EQUITY · Historical · closed Apr 29, 2020WINTOTC · EQUITY · Historical · closed Dec 22, 2017WINTDOTC · EQUITY · Historical · closed Jan 22, 2018WINTDOTC · EQUITY · Historical · closed May 20, 2020WINTWOTC · WARRANT · Historical · closed Mar 25, 2026
Recent company filings
- NT 10-K filingApr 1, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJan 7, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesDec 2, 2025
- 424B3 filingNov 21, 2025
- 10-Q filingNov 19, 2025
Registered securities in this filing
Windtree Therapeutics, Inc. · 8-K · Filed 2026-07-22
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement
As disclosed in a press release dated December 23, 2025, on December 16th, 2025 Windtree Therapeutics, Inc. (“Windtree” or “the Company”) signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. (“SPO”), a Delaware limited liability company.
Pursuant to the agreement, Windtree is entitled to 20% of any future proceeds received by SPO. This would include global commercial net revenue in acute heart failure (AHF) if approved by regulatory authorities. If SPO conducts a financing of at least $10MM to fund development of the assets, Windtree would receive a payment of $700k from the proceeds. Additionally, as part of the agreement, Windtree will transfer certain cardiovascular drug candidate development payables to SPO.